# US 2004/0081986 A1 · NF- kappa B activating gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0081986 A1
- Document ID: US20040081986A1
- Status: Published application
- Kind: A1
- Application number: 10/617,217
- Filed: 2003-07-11
- Published: 2004-04-29
- Earliest claimed: 2000-12-28
- Assignees: Asahi Kasei Pharma Corporation
- Inventors: Akio Matsuda; Goichi Honda; Shuji Muramatsu; Yukiko Nagano
- Web page: https://patentgrep.com/patent/US20040081986A1

## CPC

- C07K 14/4705: {stimulating, promoting or activating activity}
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C07K 14/4702: {Regulators; Modulating activity}
- C07K 16/18: against material from animals or humans
- G01N 33/5011: {for testing antineoplastic activity}
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- G01N 33/6872: {Intracellular protein regulatory factors and their receptors, e.g. including ion channels}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12N 2503/02: Drug screening
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/24: Immunology or allergic disorders
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Provided are proteins having NF-κ B activity, which are used for diagnosing, treating or preventing diseases associated with the excessive activation or inhibition of NF-κ B. Using plasmid pNFκ B-Luc, cDNA encoding a protein capable of activating NF-κ B has been cloned from a cDNA library constructed from human lung fibroblasts, and the DNA sequence and the deduced amino acid sequence determined. The protein, the DNA encoding the protein, a recombinant vector containing the DNA, and a transformant containing the recombinant vector are useful for screening a substance inhibiting or promoting NF-κ B activation.

## Claims

### Claim 1

A purified protein selected from the group consisting of:
(a) a protein which consists of an amino acid sequence represented by any one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180; and
(b) a protein that activates NF-κ B (Nuclear factor kappa B) and consists of an amino acid sequence having at least one amino acid deletion, substitution or addition in an amino acid sequence represented by any one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180:

### Claim 2 (depends on 1)

A purified protein that activates NF-κ B and comprises an amino acid sequence having at least 95% identity to the protein according to claim 1 over the entire length thereof.

### Claim 3

An isolated polynucleotide which comprises a nucleotide sequence encoding a protein selected from the group consisting of:
(a) a protein which comprises an amino acid sequence represented by any one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180; and
(b) a protein that activates NF-κ B and consists of an amino acid sequence having at least one amino acid deletion, substitution or addition in an amino acid sequence represented by any one of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180.

### Claim 4

An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
(a) a polynucleotide sequence represented by any one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179;
(b) a polynucleotide sequence encoding a protein that activates NF-κ B and hybridizing under stringent conditions with a polynucleotide having a polynucleotide sequence complementary to the polynucleotide sequence of (a); and
(c) a polynucleotide sequence which encodes a protein that activates NF-κ B and consists of a polynucleotide sequence having at least one nucleotide deletion, substitution or addition in a polynucleotide sequence represented by any one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179.

### Claim 5

An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:
(a) a nucleotide sequence represented by a coding region in any one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179;
(b) a nucleotide sequence encoding a protein that activates NF-κ B and hybridizing under stringent conditions with a polynucleotide having a polynucleotide sequence complementary to the polynucleotide sequence of (a); and
(c) a nucleotide sequence which encodes a protein that activates NF-κ B and consists of a nucleotide sequence having at least one nucleotide deletion, substitution or addition in a nucleotide sequence represented by a coding region in any one of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179.

### Claim 6 (depends on 3)

An isolated polynucleotide comprising a nucleotide sequence which encodes a protein that activates NF-κ B and has at least 95% identity to the polynucleotide sequence according to claim 3 over the entire length thereof.

### Claim 7 (depends on 4, 5)

An isolated polynucleotide comprising a nucleotide sequence which encodes a protein that activates NF-κ B and has at least 95% identity to the polynucleotide sequence according to claim 4 or 5 over the entire length thereof.

### Claim 8 (depends on 3, 4, 5, 6, 7)

A purified protein encoded by the polynucleotide according to any one of claims 3 to 7.

### Claim 9 (depends on 3, 4, 5, 6, 7)

A recombinant vector which comprises a polynucleotide according to any one of claims 3 to 7.

### Claim 10 (depends on 9)

A gene thrapy agent comprising the recombinant vector according to claim 9 as an active ingredient.

### Claim 11 (depends on 9)

A transformed cell which comprises the recombinant vector according to claim 9.

### Claim 12 (depends on 1, 2, 11)

A membrane of the cell according to claim 11, when the protein according to claim 1 or 2 is a membrane protein.

### Claim 13 (depends on 3, 4, 5, 6, 7)

A process for producing a protein comprising,
(a) culturing a transformed cell comprising the isolated polynucleotide according to any one of claims 3 to 7 under conditions providing expression of the encoded protein; and
(b) recovering the protein from the culture product.

### Claim 14 (depends on 1, 2, 8)

A process for diagnosing a disease or susceptibility to a disease related to expression or activity of the protein of claim 1, 2 or 8 in a subject comprising:
(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said protein in the genome of said subject; and/or
(b) analyzing the amount of expression of said protein in a sample derived from said subject.

### Claim 15

A method for screening compounds in respect of activity to inhibit or promote NF-κ B activation, which comprises the steps of:
(a) providing a cell with a gene encoding a protein that activates NF-κ B, and a component that provides a detectable signal associated with activation of NF-κ B;
(b) culturing a transformed cell under conditions, which permit the expression of the gene in the transformed cell;
(c) contacting the transformed cell with one or more compounds;
(d) measuring the detectable signal; and
(e) isolating or identifying an activator compound and/or an inhibitor compound by measuring the detectable signal.

### Claim 16

A process for producing a pharmaceutical composition, which comprises the steps of:
(a) providing a cell with a gene encoding a protein that activates NF-κ B, and a component capable of providing a detectable signal;
(b) culturing a transformed cell under conditions, which permit the expression of the gene in the transformed cell;
(c) contacting the transformed cell with one or more compounds;
(d) measuring the detectable signal;
(e) isolating or identifying an activator compound and/or an inhibitor compound by measuring the detectable signal; and
(f) optimizing the isolated or identified compound as a pharmaceutical composition.

### Claim 17

A kit for screening a compound in respect of activity to inhibit or promote NF-κ B activation, which comprises:
(a) a cell comprising a gene encoding a protein that activates NF-κ B, and a component that provides a detectable signal upon activation of NF-κ B; and
(b) reagents for measuring the detectable signal.

### Claim 18 (depends on 1, 2, 8)

A monoclonal or polyclonal antibody or a fragment thereof that specifically binds to the protein according to claim 1, 2 or 8.

### Claim 19 (depends on 1, 2, 8, 18)

The monoclonal or polyclonal antibody or a fragment thereof according to claim 18 that inhibits the action of activating NF-κ B of the protein according to claim 1, 2 or 8.

### Claim 20 (depends on 1, 2, 8)

A process for producing a monoclonal or polyclonal antibody that specifically binds to the protein according to claim 1, 2 or 8, which comprises administering the protein according to claim 1, 2 or 8 or epitope-bearing fragments thereof to a non-human animal.

### Claim 21 (depends on 3, 4, 5, 6, 7)

An antisense oligonucleotide complementary to the polynucleotide according to any one of claims 3 to 7, which prevents NF-κ B activator protein expression.

### Claim 22 (depends on 1, 2, 8)

A ribozyme which inhibits NF-κ B activation by cleavage of RNA that encodes the protein according to claim 1, 2 or 8.

### Claim 23 (depends on 3, 4, 5, 6, 7)

A double stranded nucleic acid having a nucleotide sequence corresponding to a part of the nucleotide sequence of the isolated polynucleotide according to any one of claims 3-7, which inhibit the expression of the protein that activates NF-κ B.

### Claim 24 (depends on 23)

The double stranded nucleic acid according to claim 23, wherein the nucleic acid has a nucleotide sequence corresponding to a part of the nucleotide sequence represented by SEQ ID NO: 88, and inhibits the expression of the protein having the amino acid sequence represented by SEQ ID NO: 87.

### Claim 25

A double stranded nucleic acid obtained by annealing of any one of the following oligonucleotide pairs (a)-(f):
10 (a) 5′-GUCCAGGAUAUCAUGAGUCNn-3′ (SEQ ID NO:213) 3′-NnCAGGUCCUAUAGUACUCAG-5′ (SEQ ID NO:214) (b) 5′-GAAGUCUGAAGAUCUAUCCNn-3′ (SEQ ID NO:215) 3′-NnCUUCAGACUUCUAGAUAGG-5′ (SEQ ID NO:216) (c) 5′-GCUGAAGAAGAGGUGUUCCNn-3′ (SEQ ID NO:217) 3′-NnCGACUUCUUCUCCACAAGG-5′ (SEQ ID NO:218) (d) 5′-GAUGACACAGAUGAAGCCCNn-3′ (SEQ ID NO:219) 3′-NnCUACUGUGUCUACUUCGGG-5′ (SEQ ID NO:220) (e) 5′-GCCCUCAGAGUCCAGAAUCNn-3′ (SEQ ID NO:221) 3′-NnCGGGAGUCUCAGGUCUUAG-5′ (SEQ ID NO:222) (f) 5′-GAUGACUUUGGUAUCAAACNn-3′ (SEQ ID NO:223) 3′-NnCUACUGAAACCAUAGUUUG-5′ (SEQ ID NO:224)
wherein N represents any one of G, A, T, C, and U, and n is 1 to 4.

### Claim 26 (depends on 25)

The double stranded nucleic acid according to claim 25, wherein Nn is TT or UU.

### Claim 27 (depends on 26)

A double stranded nucleic acid having one or more mutations in the sense strand of the double strand nucleic acid according to claim 26.

### Claim 28 (depends on 25, 26, 27)

A double stranded nucleic acid comprising the double stranded nucleic acid according to any one of claims 25 to 27 as a part, which inhibits the expression of the protein having the amino acid sequence represented by SEQ ID NO: 87.

### Claim 29 (depends on 25)

An expression vector capable of expressing the double stranded nucleic acid according to claim 25, wherein Nn is UU or UUU.

### Claim 30 (depends on 15, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29)

A method for treating a disease, which comprises administering to a subject an amount of compound screened by the process according to claim 15, and/or a monoclonal or polyclonal antibody or a fragment thereof according to claim 18 or 19, and/or an antisense oligonucleotide according to claim 21 and/or a ribozyme according to claim 22 and/or a double stranded nucleic acid according to any one of claims 23-28 and/or the expression vector according to claim 29 effective to treat a disease selected from the group consisting of inflammation, autoimmune diseases, infectious disease, cancers and bone diseases.

### Claim 31 (depends on 15, 18, 19, 21, 22)

A method for treating a disease, which comprises administering to a subject an amount of a compound screened by the process according to claim 15, and/or a monoclonal or polyclonal antibody or a fragment thereof according to claim 18 or 19, and/or an antisense oligonucleotide according to claim 21 and/or a ribozyme according to claim 22 effective to treat a disease selected from the group consisting of inflammation, autoimmune diseases, infectious disease, cancers and bone diseases.

### Claim 32 (depends on 16)

A pharmaceutical composition produced by the process according to claim 16 as an inhibitor or promoter of NF-κ B activation.

### Claim 33 (depends on 32)

A pharmaceutical composition according to claim 32 for the treatment of inflammation, autoimmune diseases, cancers, infectious diseases, bone diseases, AIDS, neurodegenerative diseases or ischemic disorders.

### Claim 34 (depends on 16)

A method of treating inflammation, autoimmune diseases, cancers, infectious diseases, bone diseases, AIDS, neurodegenerative diseases, or ischemic disorders, which comprises administering a pharmaceutical composition produced by the process according to claim 16 to a patient suffering from a disease associated with NF-κ B activation.

### Claim 35 (depends on 18, 19)

A pharmaceutical composition which comprises a monoclonal or polyclonal antibody or a fragment thereof according to claim 18 or 19 as an active ingredient.

### Claim 36 (depends on 21)

A pharmaceutical composition which comprises an antisense oligonucleotide according to claim 21 as an active ingredient.

### Claim 37 (depends on 22)

A pharmaceutical composition which comprises a ribozyme according to claim 22 as an active ingredient.

### Claim 38 (depends on 23, 24, 25, 26, 27, 28, 29)

A pharmaceutical composition or a gene therapy agent which comprises a double stranded nucleic acid according to any one of claims 23 to 28 and/or an expression vextor according to claim 29 as an active ingredient.

### Claim 39 (depends on 23, 24, 25, 26, 27, 28, 29)

An expression inhibiting agent for a protein having an action of activating NF-κ B, which comprises a double stranded nucleic acid according to any one of claims 23 to 28 and/or an expression vextor according to claim 29 as an active ingredient.

### Claim 40 (depends on 35, 36)

The pharmaceutical composition according to claim 35 or 36, wherein the target disease is selected from the group consisting of inflammation, autoimmune diseases, infectious diseases, cancers, bone diseases, AIDS, neurodegenerative and ischemic disorders.

### Claim 41

A method for obtaining a novel gene having a function, which comprises at least the following steps:
(a) constructing a full-length cDNA library by the oligo-capping method;
(b) cotransfecting the full-length cDNA and a plasmid containing a factor emitting a signal indicative of the presence of a protein having the function into cells; and
(c) selecting a plasmid emitting the signal.

### Claim 42

A computer-readable medium on which a sequence data set has been stored, said sequence data set comprising at least one nucleotide sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 151, 153, 155, 157,159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179, and/or at least one amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180.

### Claim 43 (depends on 42)

A method for calculating identity to other nucleotide sequences and/or amino acid sequences, which comprises comparing data on a medium according to claim 42 with data of said other nucleotide sequences and/or amino acid sequences.

### Claim 44

An insoluble substrate to which polynucleotides comprising all or part of the nucleotide sequences selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177 and 179, are fixed.

### Claim 45

An insoluble substrate to which polypeptides comprising all or a part of the amino acid sequences selected from the group consisting of SEQ ID NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170, 172, 174, 176, 178 and 180, are fixed.
